Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Ovarian Neoplasms

  Free Subscription


Articles published in PLoS One

Retrieve available abstracts of 97 articles:
HTML format
Text format



Single Articles


    January 2018
  1. SHAHZAD MMK, Felder M, Ludwig K, Van Galder HR, et al
    Trans10,cis12 conjugated linoleic acid inhibits proliferation and migration of ovarian cancer cells by inducing ER stress, autophagy, and modulation of Src.
    PLoS One. 2018;13:e0189524.
    PubMed     Text format     Abstract available


  2. WANG KH, Wang YM, Chiu LH, Chen TC, et al
    Optical imaging of ovarian cancer using a matrix metalloproteinase-3-sensitive near-infrared fluorescent probe.
    PLoS One. 2018;13:e0192047.
    PubMed     Text format     Abstract available


  3. LUO H, Xu X, Ye M, Sheng B, et al
    The prognostic value of HER2 in ovarian cancer: A meta-analysis of observational studies.
    PLoS One. 2018;13:e0191972.
    PubMed     Text format     Abstract available


  4. ZHANG R, Pu W, Zhang S, Chen L, et al
    Clinical value of ALU concentration and integrity index for the early diagnosis of ovarian cancer: A retrospective cohort trial.
    PLoS One. 2018;13:e0191756.
    PubMed     Text format     Abstract available


  5. SINGH G, Roy J, Rout P, Mallick B, et al
    Genome-wide profiling of the PIWI-interacting RNA-mRNA regulatory networks in epithelial ovarian cancers.
    PLoS One. 2018;13:e0190485.
    PubMed     Text format     Abstract available


  6. HOU S, Dai J
    Transcriptome-based signature predicts the effect of taxol in serous ovarian cancer.
    PLoS One. 2018;13:e0192812.
    PubMed     Text format     Abstract available


  7. HYLER AR, Baudoin NC, Brown MS, Stremler MA, et al
    Fluid shear stress impacts ovarian cancer cell viability, subcellular organization, and promotes genomic instability.
    PLoS One. 2018;13:e0194170.
    PubMed     Text format     Abstract available


  8. NOEL-MACDONNELL JR, Usset J, Goode EL, Fridley BL, et al
    Assessment of data transformations for model-based clustering of RNA-Seq data.
    PLoS One. 2018;13:e0191758.
    PubMed     Text format     Abstract available


  9. CHUDECKA-GLAZ A, Cymbaluk-Ploska A, Wezowska M, Menkiszak J, et al
    Could HE4 level measurements during first-line chemotherapy predict response to treatment among ovarian cancer patients?
    PLoS One. 2018;13:e0194270.
    PubMed     Text format     Abstract available


  10. CHANG LC, Huang CF, Lai MS, Shen LJ, et al
    Prognostic factors in epithelial ovarian cancer: A population-based study.
    PLoS One. 2018;13:e0194993.
    PubMed     Text format     Abstract available


  11. NEYT M, Vlayen J, Devriese S, Camberlin C, et al
    First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysis.
    PLoS One. 2018;13:e0195134.
    PubMed     Text format     Abstract available


  12. GSCHWANTLER-KAULICH D, Weingartshofer S, Rappaport-Furhauser C, Zeillinger R, et al
    Correction: Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers.
    PLoS One. 2018;13:e0196142.
    PubMed     Text format     Abstract available


  13. ZHANG T, Xu J, Deng S, Zhou F, et al
    Core signaling pathways in ovarian cancer stem cell revealed by integrative analysis of multi-marker genomics data.
    PLoS One. 2018;13:e0196351.
    PubMed     Text format     Abstract available


  14. AITHAL A, Junker WM, Kshirsagar P, Das S, et al
    Development and characterization of carboxy-terminus specific monoclonal antibodies for understanding MUC16 cleavage in human ovarian cancer.
    PLoS One. 2018;13:e0193907.
    PubMed     Text format     Abstract available


  15. ALEMAR B, Gregorio C, Herzog J, Matzenbacher Bittar C, et al
    Correction: BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
    PLoS One. 2018;13:e0197529.
    PubMed     Text format     Abstract available


  16. HECKL M, Schmoeckel E, Hertlein L, Rottmann M, et al
    The ARID1A, p53 and ss-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium.
    PLoS One. 2018;13:e0192881.
    PubMed     Text format     Abstract available


  17. HE X, Yang K, Wang H, Chen X, et al
    Expression and clinical significance of survivin in ovarian cancer: A meta-analysis.
    PLoS One. 2018;13:e0194463.
    PubMed     Text format     Abstract available


  18. CAI Q, Fan Q, Buechlein A, Miller D, et al
    Changes in mRNA/protein expression and signaling pathways in in vivo passaged mouse ovarian cancer cells.
    PLoS One. 2018;13:e0197404.
    PubMed     Text format     Abstract available


  19. TEA MM, Tan YY, Staudigl C, Eibl B, et al
    Improving comprehension of genetic counseling for hereditary breast and ovarian cancer clients with a visual tool.
    PLoS One. 2018;13:e0200559.
    PubMed     Text format     Abstract available


  20. EARP M, Tyrer JP, Winham SJ, Lin HY, et al
    Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility.
    PLoS One. 2018;13:e0197561.
    PubMed     Text format     Abstract available


  21. YEH CC, Su FH, Tzeng CR, Muo CH, et al
    Women with adenomyosis are at higher risks of endometrial and thyroid cancers: A population-based historical cohort study.
    PLoS One. 2018;13:e0194011.
    PubMed     Text format     Abstract available


  22. MITCHELL R, Buckingham L, Cobleigh M, Rotmensch J, et al
    Can chimerism explain breast/ovarian cancers in BRCA non-carriers from BRCA-positive families?
    PLoS One. 2018;13:e0195497.
    PubMed     Text format     Abstract available


  23. RHYASEN GW, Yao Y, Zhang J, Dulak A, et al
    BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors.
    PLoS One. 2018;13:e0200826.
    PubMed     Text format     Abstract available


  24. MONTAVON SARTORIUS C, Schoetzau A, Kettelhack H, Fink D, et al
    ABO blood groups as a prognostic factor for recurrence in ovarian and vulvar cancer.
    PLoS One. 2018;13:e0195213.
    PubMed     Text format     Abstract available


  25. JANSEN RJ, Alexander BH, Hayes RB, Miller AB, et al
    A mathematical model of case-ascertainment bias: Applied to case-control studies nested within a randomized screening trial.
    PLoS One. 2018;13:e0194608.
    PubMed     Text format     Abstract available


  26. WANG KH, Wang YM, Chiu LH, Chen TC, et al
    Correction: Optical imaging of ovarian cancer using a matrix metalloproteinase-3-sensitive near-infrared fluorescent probe.
    PLoS One. 2018;13:e0202610.
    PubMed     Text format     Abstract available


  27. LEE YJ, Lee IH, Kim YJ, Chung YS, et al
    Evaluation of various kinetic parameters of CA-125 in patients with advanced-stage ovarian cancer undergoing neoadjuvant chemotherapy.
    PLoS One. 2018;13:e0203366.
    PubMed     Text format     Abstract available


  28. ZHENG G, Yu H, Kanerva A, Forsti A, et al
    Familial risks of ovarian cancer by age at diagnosis, proband type and histology.
    PLoS One. 2018;13:e0205000.
    PubMed     Text format     Abstract available


  29. FUJISAWA M, Moh-Moh-Aung A, Zeng Z, Yoshimura T, et al
    Ovarian stromal cells as a source of cancer-associated fibroblasts in human epithelial ovarian cancer: A histopathological study.
    PLoS One. 2018;13:e0205494.
    PubMed     Text format     Abstract available


  30. ZHENG G, Yu H, Kanerva A, Forsti A, et al
    Correction: Familial risks of ovarian cancer by age at diagnosis, proband type and histology.
    PLoS One. 2018;13:e0206721.
    PubMed     Text format     Abstract available


  31. SHIH AJ, Menzin A, Whyte J, Lovecchio J, et al
    Identification of grade and origin specific cell populations in serous epithelial ovarian cancer by single cell RNA-seq.
    PLoS One. 2018;13:e0206785.
    PubMed     Text format     Abstract available


  32. STARBUCK KD, Szender JB, Duncan WD, Morrell K, et al
    Prognostic impact of adjuvant chemotherapy treatment intensity for ovarian cancer.
    PLoS One. 2018;13:e0206913.
    PubMed     Text format     Abstract available


  33. LIN ZP, Zhu YL, Lo YC, Moscarelli J, et al
    Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer.
    PLoS One. 2018;13:e0207399.
    PubMed     Text format     Abstract available


  34. PRAHM KP, Hogdall C, Karlsen MA, Christensen IJ, et al
    Identification and validation of potential prognostic and predictive miRNAs of epithelial ovarian cancer.
    PLoS One. 2018;13:e0207319.
    PubMed     Text format     Abstract available


  35. SHIH AJ, Menzin A, Whyte J, Lovecchio J, et al
    Correction: Identification of grade and origin specific cell populations in serous epithelial ovarian cancer by single cell RNA-seq.
    PLoS One. 2018;13:e0208778.
    PubMed     Text format     Abstract available


    January 2017
  36. FAKKERT IE, van der Veer E, Abma EM, Lefrandt JD, et al
    Elevated Bone Turnover Markers after Risk-Reducing Salpingo-Oophorectomy in Women at Increased Risk for Breast and Ovarian Cancer.
    PLoS One. 2017;12:e0169673.
    PubMed     Text format     Abstract available


  37. SEEBACHER V, Reinthaller A, Koelbl H, Concin N, et al
    The Impact of the Duration of Adjuvant Chemotherapy on Survival in Patients with Epithelial Ovarian Cancer - A Retrospective Study.
    PLoS One. 2017;12:e0169272.
    PubMed     Text format     Abstract available


  38. LEE HH, Bellat V, Law B
    Chemotherapy induces adaptive drug resistance and metastatic potentials via phenotypic CXCR4-expressing cell state transition in ovarian cancer.
    PLoS One. 2017;12:e0171044.
    PubMed     Text format     Abstract available


  39. BAI L, Wang H, Wang AH, Zhang LY, et al
    MicroRNA-532 and microRNA-3064 inhibit cell proliferation and invasion by acting as direct regulators of human telomerase reverse transcriptase in ovarian cancer.
    PLoS One. 2017;12:e0173912.
    PubMed     Text format     Abstract available


  40. PRAHM KP, Hogdall C, Karlsen MA, Christensen IJ, et al
    Clinical validation of chemotherapy predictors developed on global microRNA expression in the NCI60 cell line panel tested in ovarian cancer.
    PLoS One. 2017;12:e0174300.
    PubMed     Text format     Abstract available


  41. MA Z, Wang X, He J, Xia J, et al
    Increased expression of protein kinase CK2alpha correlates with poor patient prognosis in epithelial ovarian cancer.
    PLoS One. 2017;12:e0174037.
    PubMed     Text format     Abstract available


  42. COZZI GD, Levinson RT, Toole H, Snyder MR, et al
    Blood type, ABO genetic variants, and ovarian cancer survival.
    PLoS One. 2017;12:e0175119.
    PubMed     Text format     Abstract available


  43. BRENCICOVA E, Jagger AL, Evans HG, Georgouli M, et al
    Interleukin-10 and prostaglandin E2 have complementary but distinct suppressive effects on Toll-like receptor-mediated dendritic cell activation in ovarian carcinoma.
    PLoS One. 2017;12:e0175712.
    PubMed     Text format     Abstract available


  44. GRAUMANN R, Di Capua GA, Oyarzun JE, Vasquez MA, et al
    Expression of teneurins is associated with tumor differentiation and patient survival in ovarian cancer.
    PLoS One. 2017;12:e0177244.
    PubMed     Text format     Abstract available


  45. CHEN WC, Qiu JT, Lai CH, Huang HJ, et al
    Outcomes and prognoses of patients with ovarian cancer using bevacizumab: 6-year experience in a tertiary care hospital of northern Taiwan.
    PLoS One. 2017;12:e0175703.
    PubMed     Text format     Abstract available


  46. LIU C, Zhang Y, Jiang H, Wu H, et al
    Association between social support and post-traumatic stress disorder symptoms among Chinese patients with ovarian cancer: A multiple mediation model.
    PLoS One. 2017;12:e0177055.
    PubMed     Text format     Abstract available



  47. Correction: Blood type, ABO genetic variants, and ovarian cancer survival.
    PLoS One. 2017;12:e0178965.
    PubMed     Text format     Abstract available


  48. STAFFORD JL, Dyson G, Levin NK, Chaudhry S, et al
    Reanalysis of BRCA1/2 negative high risk ovarian cancer patients reveals novel germline risk loci and insights into missing heritability.
    PLoS One. 2017;12:e0178450.
    PubMed     Text format     Abstract available


  49. ZHANG W, Su J, Xu H, Yu S, et al
    Dicumarol inhibits PDK1 and targets multiple malignant behaviors of ovarian cancer cells.
    PLoS One. 2017;12:e0179672.
    PubMed     Text format     Abstract available


  50. BJERSAND K, Seidal T, Sundstrom-Poromaa I, Akerud H, et al
    The clinical and prognostic correlation of HRNPM and SLC1A5 in pathogenesis and prognosis in epithelial ovarian cancer.
    PLoS One. 2017;12:e0179363.
    PubMed     Text format     Abstract available


  51. SIEBENKAS C, Chiappinelli KB, Guzzetta AA, Sharma A, et al
    Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells.
    PLoS One. 2017;12:e0179501.
    PubMed     Text format     Abstract available


  52. WAN X, Bovornchutichai P, Cui Z, O'Neill E, et al
    Morphological analysis of human umbilical vein endothelial cells co-cultured with ovarian cancer cells in 3D: An oncogenic angiogenesis assay.
    PLoS One. 2017;12:e0180296.
    PubMed     Text format     Abstract available


  53. CHAO TK, Huang TS, Liao YP, Huang RL, et al
    Pyruvate kinase M2 is a poor prognostic marker of and a therapeutic target in ovarian cancer.
    PLoS One. 2017;12:e0182166.
    PubMed     Text format     Abstract available


  54. LANDSKRON J, Kraggerud SM, Wik E, Dorum A, et al
    C77G in PTPRC (CD45) is no risk allele for ovarian cancer, but associated with less aggressive disease.
    PLoS One. 2017;12:e0182030.
    PubMed     Text format     Abstract available


  55. PAULLIN T, Powell C, Menzie C, Hill R, et al
    Spheroid growth in ovarian cancer alters transcriptome responses for stress pathways and epigenetic responses.
    PLoS One. 2017;12:e0182930.
    PubMed     Text format     Abstract available


  56. ROZENBLUM E, Sotelo-Silveira JR, Kim GY, Zhu JY, et al
    Novel near-diploid ovarian cancer cell line derived from a highly aneuploid metastatic ovarian tumor.
    PLoS One. 2017;12:e0182610.
    PubMed     Text format     Abstract available


  57. PETERS IT, van Zwet EW, Smit VT, Liefers GJ, et al
    Prevalence and Risk Factors of Ovarian Metastases in Breast Cancer Patients < 41 Years of Age in the Netherlands: A Nationwide Retrospective Cohort Study.
    PLoS One. 2017;12:e0168277.
    PubMed     Text format     Abstract available


  58. ZHU J, Wen H, Ju X, Bi R, et al
    Clinical Significance of Programmed Death Ligand1 and Intra-Tumoral CD8+ T Lymphocytes in Ovarian Carcinosarcoma.
    PLoS One. 2017;12:e0170879.
    PubMed     Text format     Abstract available


  59. SEEBACHER V, Aust S, D'Andrea D, Grimm C, et al
    Development of a tool for prediction of ovarian cancer in patients with adnexal masses: Value of plasma fibrinogen.
    PLoS One. 2017;12:e0182383.
    PubMed     Text format     Abstract available


  60. HAIMOVICH JS, Venkatesh AK, Shojaee A, Coppi A, et al
    Discovery of temporal and disease association patterns in condition-specific hospital utilization rates.
    PLoS One. 2017;12:e0172049.
    PubMed     Text format     Abstract available


  61. JIA ZH, Jia Y, Guo FJ, Chen J, et al
    Phosphorylation of STAT3 at Tyr705 regulates MMP-9 production in epithelial ovarian cancer.
    PLoS One. 2017;12:e0183622.
    PubMed     Text format     Abstract available


  62. CHUNG YS, Kim YJ, Lee I, Lee JY, et al
    Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer.
    PLoS One. 2017;12:e0183754.
    PubMed     Text format     Abstract available


  63. ZHANG H, Lu J, Lu Y, Zhou J, et al
    Prognostic significance and predictors of the system inflammation score in ovarian clear cell carcinoma.
    PLoS One. 2017;12:e0177520.
    PubMed     Text format     Abstract available


  64. ROSSO M, Majem B, Devis L, Lapyckyj L, et al
    E-cadherin: A determinant molecule associated with ovarian cancer progression, dissemination and aggressiveness.
    PLoS One. 2017;12:e0184439.
    PubMed     Text format     Abstract available


  65. AYYAGARI VN, Diaz-Sylvester PL, Hsieh TJ, Brard L, et al
    Evaluation of the cytotoxicity of the Bithionol-paclitaxel combination in a panel of human ovarian cancer cell lines.
    PLoS One. 2017;12:e0185111.
    PubMed     Text format     Abstract available


  66. GRANATA V, Fusco R, Catalano O, Avallone A, et al
    Diagnostic accuracy of magnetic resonance, computed tomography and contrast enhanced ultrasound in radiological multimodality assessment of peribiliary liver metastases.
    PLoS One. 2017;12:e0179951.
    PubMed     Text format     Abstract available


  67. YANAGIDA S, Anglesio MS, Nazeran TM, Lum A, et al
    Clinical and genetic analysis of recurrent adult-type granulosa cell tumor of the ovary: Persistent preservation of heterozygous c.402C>G FOXL2 mutation.
    PLoS One. 2017;12:e0178989.
    PubMed     Text format     Abstract available


  68. LIN KT, Sun SP, Wu JI, Wang LH, et al
    Low-dose glucocorticoids suppresses ovarian tumor growth and metastasis in an immunocompetent syngeneic mouse model.
    PLoS One. 2017;12:e0178937.
    PubMed     Text format     Abstract available


  69. SUNG PL, Wen KC, Chen YJ, Chao TC, et al
    The frequency of cancer predisposition gene mutations in hereditary breast and ovarian cancer patients in Taiwan: From BRCA1/2 to multi-gene panels.
    PLoS One. 2017;12:e0185615.
    PubMed     Text format     Abstract available


  70. ZHU XM, Sun WF
    Association between matrix metalloproteinases polymorphisms and ovarian cancer risk: A meta-analysis and systematic review.
    PLoS One. 2017;12:e0185456.
    PubMed     Text format     Abstract available


  71. TAO X, Chen L, Ge S, Cai L, et al
    Weigh the pros and cons to ovarian reserve before stripping ovarian endometriomas prior to IVF/ICSI: A meta-analysis.
    PLoS One. 2017;12:e0177426.
    PubMed     Text format     Abstract available


  72. HARTER P, Hauke J, Heitz F, Reuss A, et al
    Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1).
    PLoS One. 2017;12:e0186043.
    PubMed     Text format     Abstract available


  73. GUO Z, Wang X, Cheng D, Xia Z, et al
    Correction: PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer.
    PLoS One. 2017;12:e0186965.
    PubMed     Text format     Abstract available


  74. VALIANATOS G, Valcikova B, Growkova K, Verlande A, et al
    A small molecule drug promoting miRNA processing induces alternative splicing of MdmX transcript and rescues p53 activity in human cancer cells overexpressing MdmX protein.
    PLoS One. 2017;12:e0185801.
    PubMed     Text format     Abstract available


  75. FORNARO L, Vivaldi C, Lin D, Xue H, et al
    Prognostic relevance of a T-type calcium channels gene signature in solid tumours: A correlation ready for clinical validation.
    PLoS One. 2017;12:e0182818.
    PubMed     Text format     Abstract available


  76. YANG L, Zhang B, Xing G, Du J, et al
    Neoadjuvant chemotherapy versus primary debulking surgery in advanced epithelial ovarian cancer: A meta-analysis of peri-operative outcome.
    PLoS One. 2017;12:e0186725.
    PubMed     Text format     Abstract available


  77. GENG X, Liu Y, Diersch S, Kotzsch M, et al
    Clinical relevance of kallikrein-related peptidase 9, 10, 11, and 15 mRNA expression in advanced high-grade serous ovarian cancer.
    PLoS One. 2017;12:e0186847.
    PubMed     Text format     Abstract available


  78. QIN L, Li T, Liu Y
    High SLC4A11 expression is an independent predictor for poor overall survival in grade 3/4 serous ovarian cancer.
    PLoS One. 2017;12:e0187385.
    PubMed     Text format     Abstract available


  79. CHESNAIS M, Lecuru F, Mimouni M, Ngo C, et al
    A pre-operative predictive score to evaluate the feasibility of complete cytoreductive surgery in patients with epithelial ovarian cancer.
    PLoS One. 2017;12:e0187245.
    PubMed     Text format     Abstract available


  80. ALEMAR B, Gregorio C, Herzog J, Matzenbacher Bittar C, et al
    BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
    PLoS One. 2017;12:e0187630.
    PubMed     Text format     Abstract available


  81. GSCHWANTLER-KAULICH D, Weingartshofer S, Rappaport-Furhauser C, Zeilinger R, et al
    Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers.
    PLoS One. 2017;12:e0189641.
    PubMed     Text format     Abstract available


  82. KUROKI LM, Jin X, Dmitriev IP, Kashentseva EA, et al
    Adenovirus platform enhances transduction efficiency of human mesenchymal stem cells: An opportunity for cellular carriers of targeted TRAIL-based TR3 biologics in ovarian cancer.
    PLoS One. 2017;12:e0190125.
    PubMed     Text format     Abstract available


  83. COUTTENIER A, Lacroix O, Vaes E, Cardwell CR, et al
    Statin use is associated with improved survival in ovarian cancer: A retrospective population-based study.
    PLoS One. 2017;12:e0189233.
    PubMed     Text format     Abstract available


  84. OBATA T, Nakamura M, Mizumoto Y, Iizuka T, et al
    Dual expression of immunoreactive estrogen receptor beta and p53 is a potential predictor of regional lymph node metastasis and postoperative recurrence in endometrial endometrioid carcinoma.
    PLoS One. 2017;12:e0188641.
    PubMed     Text format     Abstract available


  85. JIN D, Lee H
    FGMD: A novel approach for functional gene module detection in cancer.
    PLoS One. 2017;12:e0188900.
    PubMed     Text format     Abstract available


  86. CHEN Y, Bieber MM, Bhat NM, Teng NNH, et al
    Ovarian carcinoma glyco-antigen targeted by human IgM antibody.
    PLoS One. 2017;12:e0187222.
    PubMed     Text format     Abstract available


    January 2016
  87. TUMBARELLO DA, Andrews MR, Brenton JD
    SPARC Regulates Transforming Growth Factor Beta Induced (TGFBI) Extracellular Matrix Deposition and Paclitaxel Response in Ovarian Cancer Cells.
    PLoS One. 2016;11:e0162698.
    PubMed     Text format     Abstract available


  88. XIAO X, Cai F, Niu X, Shi H, et al
    Association between P16INK4a Promoter Methylation and Ovarian Cancer: A Meta-Analysis of 12 Published Studies.
    PLoS One. 2016;11:e0163257.
    PubMed     Text format     Abstract available


  89. LI L, Luo Q, Xie Z, Li G, et al
    Characterization of the Expression of the RNA Binding Protein eIF4G1 and Its Clinicopathological Correlation with Serous Ovarian Cancer.
    PLoS One. 2016;11:e0163447.
    PubMed     Text format     Abstract available


  90. IGNACIO RM, Kabir SM, Lee ES, Adunyah SE, et al
    NF-kappaB-Mediated CCL20 Reigns Dominantly in CXCR2-Driven Ovarian Cancer Progression.
    PLoS One. 2016;11:e0164189.
    PubMed     Text format     Abstract available


  91. POCHECHUEVA T, Chinarev A, Schoetzau A, Fedier A, et al
    Blood Plasma-Derived Anti-Glycan Antibodies to Sialylated and Sulfated Glycans Identify Ovarian Cancer Patients.
    PLoS One. 2016;11:e0164230.
    PubMed     Text format     Abstract available


  92. FEDOSEIENKO A, Wieringa HW, Wisman GB, Duiker E, et al
    Nuclear COMMD1 Is Associated with Cisplatin Sensitivity in Ovarian Cancer.
    PLoS One. 2016;11:e0165385.
    PubMed     Text format     Abstract available


  93. SUN S, Cai J, Yang Q, Zhu Y, et al
    Prognostic Value and Implication for Chemotherapy Treatment of ABCB1 in Epithelial Ovarian Cancer: A Meta-Analysis.
    PLoS One. 2016;11:e0166058.
    PubMed     Text format     Abstract available


  94. PENNINGTON M, Gentry-Maharaj A, Karpinskyj C, Miners A, et al
    Long-Term Secondary Care Costs of Endometrial Cancer: A Prospective Cohort Study Nested within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    PLoS One. 2016;11:e0165539.
    PubMed     Text format     Abstract available


  95. RASOOL M, Malik A, Basit Ashraf MA, Parveen G, et al
    Evaluation of Matrix Metalloproteinases, Cytokines and Their Potential Role in the Development of Ovarian Cancer.
    PLoS One. 2016;11:e0167149.
    PubMed     Text format     Abstract available


  96. POWELL CD, Paullin TR, Aoisa C, Menzie CJ, et al
    The Heat Shock Transcription Factor HSF1 Induces Ovarian Cancer Epithelial-Mesenchymal Transition in a 3D Spheroid Growth Model.
    PLoS One. 2016;11:e0168389.
    PubMed     Text format     Abstract available


  97. TAO F, Ruan S, Liu W, Wang L, et al
    Fuling Granule, a Traditional Chinese Medicine Compound, Suppresses Cell Proliferation and TGFbeta-Induced EMT in Ovarian Cancer.
    PLoS One. 2016;11:e0168892.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: